EXTEND (Eltrombopag Extended Dosing Study)
Public ClinicalTrials.gov record NCT00351468. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open-label, dose-adjustment, extension study to evaluate the safety and efficacy of eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP) who have previously been enrolled in an eltrombopag trial. This study will allow adjustment of the eltrombopag dose to achieve an individualized dose and schedule for each subject. In addition, the ability to reduce the dose of concomitant ITP medications in the presence of eltrombopag, while maintaining platelet counts = 50,000/μL will be investigated.
Study identification
- NCT ID
- NCT00351468
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 302 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2006 (Type not available)
- Primary completion
- Jul 2015 (Actual)
- Completion
- Jul 2015 (Actual)
- Last update posted
- Apr 17, 2017
2006 – 2015
United States locations
- U.S. sites
- 23
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Huntsville | Alabama | 35805 | — |
| Novartis Investigative Site | Mobile | Alabama | 36608 | — |
| Novartis Investigative Site | Jonesboro | Arkansas | 72401 | — |
| Novartis Investigative Site | Duarte | California | 91010 | — |
| Novartis Investigative Site | Los Angeles | California | 90033 | — |
| Novartis Investigative Site | San Francisco | California | 94143 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30341 | — |
| Novartis Investigative Site | Savannah | Georgia | 31405 | — |
| Novartis Investigative Site | Peoria | Illinois | 61614 | — |
| Novartis Investigative Site | New Orleans | Louisiana | 70115 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02114 | — |
| Novartis Investigative Site | Detroit | Michigan | 48202 | — |
| Novartis Investigative Site | Brunsville | Minnesota | 55337 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87109 | — |
| Novartis Investigative Site | New York | New York | 10021 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44106 | — |
| Novartis Investigative Site | Portland | Oregon | 97227 | — |
| Novartis Investigative Site | Lubbock | Texas | 79410 | — |
| Novartis Investigative Site | Arlington | Virginia | 22205 | — |
| Novartis Investigative Site | Seattle | Washington | 98109 | — |
| Novartis Investigative Site | Tacoma | Washington | 98405 | — |
| Novartis Investigative Site | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00351468, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 17, 2017 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00351468 live on ClinicalTrials.gov.